

RESEARCH

Open Access



CircPSMC3 suppresses the proliferation and metastasis of gastric cancer by acting as a competitive endogenous RNA through sponging miR-296-5p

Dawei Rong^{1†}, Chen Lu^{1†}, Betty Zhang², Kai Fu¹, Shuli Zhao^{3*}, Weiwei Tang^{1*} and Hongyong Cao^{1*}

Abstract

Background: Circular RNAs (circRNAs) are a class of non-coding RNAs with a loop structure, but its functions remain largely unknown. Growing evidence has revealed that circRNAs play a striking role as functional RNAs in the progression of malignant disease. However, the precise role of circRNAs in gastric cancer (GC) remains unclear.

Methods: CircRNAs were determined by human circRNA array analysis and quantitative reverse transcription polymerase reaction. Luciferase reporter, RNA pull down, and fluorescence in situ hybridization assays were employed to test the interaction between circPSMC3 and miR-296-5p. Ectopic over-expression and siRNA-mediated knockdown of circPSMC3, proliferation, migration and invasion in vitro, and in vivo experiment of metastasis were used to evaluate the function of circPSMC3.

Results: CircPSMC3 rather than liner PSMC3 mRNA was down-regulated in GC tissues, corresponding plasmas from GC patients as well as GC cell lines compared to normal controls. Lower circPSMC3 expression in GC patients was correlated with higher TNM stage and shorter overall survival. Over-expression of circPSMC3 and miR-296-5p inhibitor could inhibit the tumorigenesis of gastric cancer cells in vivo and vitro whereas co-transfection of circPSMC3 and miRNA-296-5p could counteract this effect. Importantly, we demonstrated that circPSMC3 could act as a sponge of miR-296-5p to regulate the expression of Phosphatase and Tensin Homolog (PTEN), and further suppress the tumorigenesis of gastric cancer cells.

Conclusion: Our study reveals that circPSMC3 can serve as a novel potential circulating biomarker for detection of GC. CircPSMC3 participates in progression of gastric cancer by sponging miRNA-296-5p with PTEN, providing a new insight into the treatment of gastric cancer.

Keywords: Gastric cancer, circPSMC3, miR-296-5p, PTEN, Therapy

Introduction

Gastric cancer (GC) is the fifth most common cancer in the world and the third most common cause of cancer death worldwide [1]. It tends to metastasize into neighboring tissues and organs through lymph nodes and

generate more cancer cells through the blood [2]. Although there have been many advancements in the diagnosis and treatment of GC, recurrence and metastasis are still occurring at high rates [3, 4]. Improvements in clinical care for these patients are limited by the lack of clarity surrounding the molecular mechanism in GC development [5]. Thus, it is urgently necessary to explore new potential biomarkers and their molecular mechanisms to better understand the pathophysiology of gastric malignancies.

Circular RNAs (circRNAs) are a new class of endogenous non-coding RNAs characterized by covalently closed

* Correspondence: shulizhao79@163.com; 1243773473twww@sina.com; caohongy6167@163.com

[†]Dawei Rong and Chen Lu contributed equally to this work.

³Department of General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China

¹Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China

Full list of author information is available at the end of the article



loops without 5' to 3' polar or polyadenylation tails [6]. Previous studies have shown that circRNAs are formed by the back-splicing of pre-mRNA transcripts from genes with five different forms [7]. CircRNAs are stable, conserved and abundant in various cancer tissues or cell lines, as tissue/developmental stage-specific circRNAs are usually notable [8, 9]. Kuei-Yang Hsiao et al. found that circRNA CCDC66 could promote the progression and metastasis of colon cancer [10]. Studies on the molecular mechanism of circRNAs indicate that circRNAs can act as a competitive endogenous RNA (ceRNA) to regulate downstream genes associated with diseases by binding to miRNAs [11–13]. Xuetao Cao et al. found that circMTO1 might regulate the progression of hepatocellular carcinoma (HCC) by regulating the expression of p21 as a sponge of oncogenic miR-9, which can be used as a potential target for HCC therapy and a prognostic indicator for low patient survival [14]. Zhenyu Zhong et al. indicated that circMYLK could act as ceRNA of miR-29a, further promoting the progression of Epithelial-Mesenchymal Transition (EMT) in bladder cancer by activating VEGFA/VEGFR2 and Ras/ERK signaling pathways [15].

MicroRNAs (miRNAs), as a conserved small regulatory non-coding RNA, have been demonstrated to involve many biological functions in different diseases [16]. Many studies have reported that miRNAs can regulate by different circRNAs and lncRNAs to further regulate gene expression [17–19]. Yawei Li et al. found that circHIPK3, which contains two key binding sites of miR-558, directly regulates miR-558 function to inhibit heparanase (HPSE) expression. Their findings suggest that circHIPK3 acts as a “miRNA sponge” and identifies circHIPK3 as a new therapeutic target for patients with bladder cancer [20].

In this study, based on the results of circRNA arrays, we identified a circular RNA termed circPSMC3 derived from PSMC3 gene. CircPSMC3 was down-regulated in tissues, corresponding plasmas from GC patients as well as GC cell lines and could act as a sponge of miRNA-296-5p to regulate the expression of Phosphatase and Tensin Homolog (PTEN), and further suppress the tumorigenesis of GC cells. Our findings provide insight into the treatment of gastric cancer and reveal a novel potential circulating biomarker for detection of GC.

Materials and methods

Cell cultures and patient tissues

Human gastric cancer cell lines (BGC823, MGC803, SGC7901, AGS, and MKN45) were purchased from Shanghai Institutes for Biological Sciences, China. The human gastric epithelial cell line GES-1 was obtained from the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences (Beijing, China). All cell

lines were cultured in RPMI 1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco, Vienna, Austria) and in a humidified incubator containing 5% CO₂ at 37 °C.

One hundred and-six samples of GC tissues were matched to adjacent normal tissues and 10 ml pre-operative blood venous blood were collected from the GC patients treated in Department of General Surgery, Nanjing Hospital, Nanjing Medical University during 2013 to 2016 in accordance with the Helsinki Declaration. Twenty-one samples of 10 ml normal venous blood were randomly obtained from the 50–90 years old individuals without any underlying diseases in physical examination center of Nanjing Hospital during 2015 to 2016. All these specimens were frozen in liquid nitrogen and stably stored at –80 °C until RNA extraction. Histological and pathological diagnoses of these specimens were confirmed and classified by two experienced clinical pathologists. Informed consent from these patients has been obtained before specimen collection. This project was approved by the Ethics Committee of Nanjing Medical University.

Quantitative reverse transcription polymerase reaction (qRT-PCR)

According to the manufacturer's protocol, total RNAs from tissues, plasma and cells were isolated by using TRIzol reagent (Invitrogen, CA, USA). For circRNA and mRNA, cDNA was synthesized by using reverse transcription kit (Takara, Otsu, Japan) and for miRNA, total RNAs were reversed using RiboBio reverse transcription kit (Guangzhou, China). Quantification of mRNA and circular RNA was performed by using a SYBR Green PCR Kit (Takara, Otsu, Japan), and miRNA PCR was performed by using a SYBR Green PCR Kit (RiboBio, Guangzhou, China). All primer sequences were designed and synthesized by Genery (Nanjing, China). CircPSMC3 expression level was detected using the following primer pair: 5'-GTTTAGGGTCCCCTGCCCTTG-3' (Forward, or F) and 5'-GTGTTGGGCTGGAAGCCATC-3' (Reverse, or R). The primer pair of PSMC3 is 5'-AGACGCTGCCACAGAGTATG-3' (F) and 5'-CTTTGGAGGTTGGATCCCC-3' (R). GAPDH was used to normalize the mRNA and circRNA expression levels and U6 was used to normalize the miRNA expression levels before calculation.

RNase R treatment

Total RNA (10 µg) of gastric cancer cell lines was mixed with 40 U RNase R at 37 °C for 2 h. To assess the stability of circPSMC3 and line PSMC3 mRNA, the expression levels were determined by using qRT-PCR.

Oligonucleotide transfection

Si-circPSMC3, miRNA-296-5p mimic, miRNA-296-5p inhibitor and their related control oligonucleotide were designed and synthesized by RiboBio (Guangzhou, China). The sequence of siRNA: siRNA-1: TAGGGTCCCTGCCCC TTTGA, siRNA-2: GGGTCCCTGCCCTTTGACA, siRNA-3: TCCCTGCCCTTTGACAGTG. All transfections were performed by the final concentration of 60 nM of miRNA mimics and 100 nM of miRNA inhibitor and si-circPSMC3. Lipofectamine 2000 reagent (Invitrogen) was used as transfection medium.

Plasmids construction and stable transfection

To isolate stable human gastric cancer cells over-expressing circPSMC3, circPSMC3 cDNA was synthesized cloned into pcD-ciR and pcDNA3 vector and lentivirus (Hanheng, Shanghai, China). According to the manufacturer's instructions, human gastric cancer cell lines, MGC803 and BGC823 were infected with lentivirus at a multiplicity of infection of 50. All cell lines were followed by selection with 2 µg/mL puromycin for 2 weeks.

Luciferase reporter assay

The wild-type and mutant fragments in 3'-UTR of circPSMC3 related with miRNA-296-5p binding site were designed, synthesized and inserted into pGL3-basic vectors (Realgene, Nanjing, China), then pGL3-basic vectors and miRNA-296-5p mimics or inhibitor or circPSMC3 overexpressing lentivirus were co-transfected to 293 T cell respectively. After 48 h, according to the manufacturer's instructions, luciferase activity in co-transfected cells were collected and detected by the dual-luciferase reporter assay system (Promega).

Biotin-coupled probe RNA pull down assay

Biotin-coupled probe RNA pull down assay was performed. To pull down the miRNA by circRNA, MGC803 and BGC823 with transfected with miRNA-296-5p mimics were lysed and incubated with Biotin-coupled probe of circPSMC3 which was pre-bound on magnetic beads. For 2 h, target RNA was pulled by the RNeasy Mini Kit (QIAGEN, Germany). Then the pull-down product was extracted, reversed and placed through q-PCR. To pull down the circRNA by miRNA, MGC803 and BGC823 with circPSMC3 over-expression and Biotin-coupled probe of miRNA-296-5p were processed through the same protocol.

Fluorescence in situ hybridization (FISH)

The fluorescence in situ hybridization assay was performed to detect the presence of circPSMC3 and miRNA-296-5p by using Fluorescence in Situ Hybridization Kit (RiboBio, Guangzhou, China). CircPSMC3 was captured with

Cy5-labeled probe and miRNA-296-5p was captured with Cy3-labeled probe respectively. After prehybridization, circPSMC3 probe and miRNA-296-5p probe were hybridized in prepared hybridization buffer in MGC803 cells. Nuclei were marked by staining with 4,6-diamidino-2-phenylindole (DAPI). Confocal microscopy was used to better visualize the presence of circPSMC3 and miRNA-296-5p.

Cell counting kit-8 proliferation assay and 5-Ethynyl-20-deoxyuridine (EdU) incorporation assay

GC cells were seeded in 96 wells with the density of 4000 cells per well. Seeded cells were treated with 10 µl of CCK8 solution (Ribobio, Guangzhou, China) after cultured at 0 h, 24 h, 48 h, 72 h, 96 h, respectively. Then the absorbance of cells at each time was analyzed at 450 nm by microplate reader according to the manufacturer's instructions (Synergy4; BioTek, Winooski, VT, USA). The EdU assay was performed to assess the proliferation of cells by using a Cell-Light EdU DNA Cell Proliferation Kit (RiboBio, Guangzhou, China). GC cells were plated in 24 wells and were cultured for 24 h. These two cell lines were fixed using 4% paraformaldehyde after incubation with 50 mM EdU solution for 2 h. Then according to the manufacturer's protocol, cell lines were sealed with Apollo Dye Solution and Hoechst 33342 in order. The EdU cell lines were photographed and counted under an Olympus FSX100 microscope (Olympus, Tokyo, Japan).

Transwell migration and invasion assays

For this assay, according to the manufacturer's protocol, GC cells were seeded in upper chambers with 200 µl of serum-free medium. The transwell chamber (Corning, NY, USA) was paved with matrigel mix (BD Biosciences, San Jose, CA, USA) for invasion assays and without matrigel mix for migration assays. The bottom chamber was filled with medium and 10% FBS as a gastric cancer cell chemoattractant. After incubation for 24 h, the upper chambers were fixed and then stained by crystal violet (Kaigen, Nanjing, China) for 15 min. For visualization, the cell lines were photographed and counted in different five fields.

Cell apoptosis assays

GC cells were stained with FITC and PI from the Annexin V-FITC/Propidium Iodide (PI) Apoptosis Detection Kit (BD Biosciences #556547). FACSscan (BD Biosciences, San Jose, CA, USA) was used to analysis stained cells and all apoptosis data of different cell lines was analyzed by Flowjo V10 software (Tree Star, San Francisco, CA, USA).

Western blot

Cells were lysed in RIPA lysis buffer (RIPA, Beyotime, China). The protein was prepared and quantified by bicinchoninic acid (BCA) analysis (Beyotime, China). The same amounts of protein were extracted by 10% SDS-PAGE and transferred onto a PVDF membrane (Millipore, Schwalbach, Germany). The blocked protein with 5% skim milk powder was incubated with primary antibody anti-PTEN (#3285, Cell Signaling Technology), anti-YYM (#66281-1-Ig, Proteintech), anti-GAPDH (#ab181602, Abcam) at 4 °C for 12 h. Then the prepared membranes were incubated with secondary antibody (1:5000) for 2 h. Finally, the blots were detected by enhanced chemiluminescence kit (Pierce, Waltham, MA, USA) and related data was analyzed by Image Lab Software.

Xenografts in mice

The animal assay was approved by the animal management committee of Nanjing Medical University, and all experimental procedures and animal care were in accordance with the institutional ethics guidelines for animal experiments. To create the xenograft tumor model, 20 5-week-old male nude mice were separated randomly into over-circPSMC3 group and NC group ($n = 10$ for each group). About 1×10^7 circPSMC3 over-expressing MGC803 cells were subcutaneously injected into the axilla of the nude mice respectively. The volume of all injected nude mice was measured every 3 days by using digital calipers. After 35 days, all injected nude mice were sacrificed, excised tumor weights were measured and tumor tissues were studied by hematoxylin and eosin (H&E) and IHC staining. To produce the nude mice metastasis model, 20 5-week-old male nude mice were separated randomly into over-circPSMC3 group and NC group ($n = 10$ for each group). About 2×10^6 circPSMC3 over-expressing MGC803 cells were tail-vein injected into 20 5-week-old male BALB/c nude mice respectively. Six weeks later, the nude mice were sacrificed; pulmonary metastases nodules were counted by three pathologists after the lungs were removed by experienced surgeons. The lungs removed were studied by using hematoxylin-eosin staining.

Statistical analysis

The analyses were mainly performed by using SPSS 19.0 (IBM, SPSS, and Chicago, IL, USA) and p -value < 0.05 was demarcated to be statistically significant. Comparison of continuous data was analyzed using an independent t -test between the two groups, whereas categorical data was analyzed by the chi-square test. Kaplan-Meier method was mainly used to assess the survival rate and analyzed by using log rank test.


Results

CircPSMC3 is significantly down regulated in gastric cancer and associated with poor prognosis

To investigate the role of circRNAs in the development of gastric cancer, the circRNA expression signatures in gastric cancer plasma were explored by using circRNA microarray analysis using plasma samples from 10 GC patients, including 5 patients with no lymph node metastasis and the other 5 patients with lymph node metastasis, and 5 normal individuals. The result showed that 6405 circRNAs in lymph node metastasis group and normal group (Fig. 1a) and 3443 circRNA in lymph node metastasis group and no lymph node metastasis group (Fig. 1b) were significantly altered with fold change > 2.0 and $P < 0.05$. GO pathway analysis suggest that these differentially expressed circRNAs are relevant to several vital physiological processes, molecular functions, and critical signaling pathways in two groups (Fig. 1c-d).

We selected a total of 6 circRNAs based on the multiple fold difference in circRNA microarray and then verified the findings in a small sample of plasmas by using qRT-PCR as well as the structure, length, and source of circRNA (Additional file 1: Figure S1a). Results showed that a novel circRNA named circPSMC3, which has never been reported in previous literature, has a significantly lower expression in GC plasmas compared to normal controls, which was then picked out for further study. The spliced mature sequence length of circPSMC3 derived from the PSMC3 gene is 502 bp according to circbase database (<http://www.circbase.org/>) (Fig. 1e) and circPSMC3 is derived from exons, while no other subtypes of circPSMC3 are found. The stability of circPSMC3 was evaluated and results showed that circPSMC3 harbors a loop structure with the resistance to digestion by RNase R (Fig. 1f), while PSMC3 mRNA could be degraded by RNase R (Fig. 1g).

Given that the tremendous diagnostic and therapeutic role of circRNAs in GC, we explored the clinical value of circPSMC3 by detecting its expression in GC samples. Results indicated circPSMC3 had significantly lower expression in GC plasmas (Fig. 1h), tissues (Fig. 1i) and cells (Fig. 1j) compared to normal controls. In addition, circPSMC3 expression was lower in preoperative blood from GC patients with lymph node metastasis compared to those patients without lymph node metastasis (Fig. 1h). Clinicopathological features showed that down-expression of circPSMC3 was negatively associated with TNM stage (Table 1, $P = 0.000$) and lymphatic metastasis (Table 1, $P = 0.021$). However, circPSMC3 was not associated with the gender, age, size, or histological grade. Furthermore, the area under the ROC curve (AUC) of circPSMC3 in distinguishing GC plasmas and normal ones was 0.9326 (Fig. 1k) and the cut-off value was -9.965 with the sensitivity of 85.85% and specificity of 95.24%. Kaplan-Meier



overall survival curve revealed that patients with lower circPSMC3 expression showed a reduced overall survival time (Fig. 1l).

CircPSMC3 plays a suppression role in gastric cancer cells in vitro

To evaluate the role of circPSMC3 in GC cells, three si-RNAs against circPSMC3 were designed to silence circPSMC3 without influencing PSMC3 mRNA level in BGC823 and SGC7901 cells (Additional file 1: Figure S1b-1d) and finally si-circPSMC3#1 was chosen for the following experiment with its high inhibitory efficiency. The circular transcript expression vector circPSMC3 was

successfully constructed in MGC803 and AGS cells (Fig. 2a), as it could increase circPSMC3 expression level rather than PSMC3 mRNA (Additional file 1: Figure S1e-1f). The results of CCK-8 and EdU assay showed that si-circPSMC3 could promote cell proliferation in BGC823 and SGC7901 cell lines, whereas over-expression of circPSMC3 (named circ-PSMC3) might inhibit cell proliferation in MGC823 and AGS cell lines (Fig. 2b-c). Wound healing assay showed that silencing of circPSMC3 significantly increased the cell mobility, while over-expression of circPSMC3 might inhibit the cell mobility (Fig. 2d). The result of cell invasion assay showed that down regulation of circPSMC3 significantly increased cell invasion and

Table 1 Correlations between circPSMC3 expression in plasmas and clinical characteristics in GC patients

characteristic	case	circPSMC3 expression		ρ value
		low	high	
All cases	106	91	15	
Age (years)				0.530
< 65	40	34	6	
≥65	66	57	9	
Gender				0.250
Female	37	34	3	
Male	69	57	12	
Tumor size (cm)				0.266
< 5	42	34	8	
≥5	64	57	7	
Histological grade				0.309
High	23	18	5	
Middle-low	83	73	10	
Lymph node metastasis				0.021*
Negative	27	19	8	
Positive	78	72	7	
TNM stage				0.000*
I–II	38	24	14	
III–IV	68	67	1	

*indicates $P < 0.05$

over-expression of circPSMC3 exhibited the opposite role (Fig. 2e).

CircPSMC3 directly binds to miR-296-5p and suppresses miR-296-5p activity

Given that circRNAs could bind to different miRNAs and regulate downstream genes, we found that circPSMC3 possessed a complementary sequence to miR-296-5p seed region by bioinformatics analysis through Circinteractome database (<https://circinteractome.nia.nih.gov/>). To confirm the website prediction, the biotin-coupled probe pull-down assay was performed and the results showed miR-296-5p and circPSMC3 were detected in the circPSMC3 pulled-down pellet compared with the control group (Fig. 3a). Furthermore, the result of FISH indicated that circPSMC3 was co-localized with miR-296-5p in the cytoplasm of MGC803 cell lines (Fig. 3b).

In addition, luciferase reporters with either the wild type circPSMC3 sequence (WT) or the sequence with mutated binding sites of miR-296-5p (Mut) into the 3' UTR of renilla luciferase showed that miR-296-5p over-expression could significantly reduce the luciferase activities of WT reporter rather than mutant one (Fig. 3c). QRT-PCR further confirmed that circPSMC3 knockdown could increase the miR-296-5p level and circ-PSMC3 had an opposite role in GC cell lines (Fig. 3d). However, miR-296-5p

failed to influence circPSMC3 level (Fig. 3e). Collectively, these revealed that circPSMC3 could bind to miR-296-5p to further regulate its expression level.

MiR-296-5p targets PTEN and promotes the proliferation and invasion of gastric cancer cells


According to miRanda database prediction (<http://mirdb.org/>), miR-296-5p could target PTEN mRNA 3' UTR with a high score.

This interaction was confirmed by performing luciferase reporter assays. The results showed that the over-expression of miR-296-5p could significantly reduce the activity of a luciferase reporter compared to miR-NC and the inhibition of the miR-296-5p may evidently increase the luciferase activity compared with inh-NC with wild type PTEN sequence (WT), however, these effect disappeared with mutated binding sites of miR-296-5p (Mut)(Fig. 4a). The knockdown or over-expression model of miR-296-5p was successfully established (Additional file 1: Figure S1g-1h). We found that miR-296-5p over-expression significantly reduced the PTEN mRNA levels in GC cells (Fig. 4b). Western blot further confirmed that transfection of miR-296-5p mimics could reduce PTEN expression (Fig. 4c). These results showed that miR-296-5p could negatively regulate the expression of PTEN.

The role of miR-296-5p on the GC cell proliferation, viability, invasion, and migration was evaluated. The results indicated that over-expression of miR-296-5p promoted the proliferation (Fig. 4d-e), migration (Fig. 4f) and invasion (Fig. 4g) of GC cells. However, down expression of miR-296-5p might exert an opposite effect (Fig. 4d). These results suggest that miR-296-5p could target PTEN and further promote the development of GC partially.

CircPSMC3 suppresses the proliferation and invasion of gastric cancer by sponging miR-296-5p to regulate PTEN

In order to further explore the interaction among circPSMC3, miR-296-5p and PTEN, we performed luciferase reporter assays. The data showed that the over-expression of circPSMC3 could significantly increase the activity of a luciferase reporter, however, the co-transfection of circPSMC3 and miR-296-5p may eliminate this effect with wild type PTEN sequence (WT), and these effects disappeared with mutated binding sites of miR-296-5p (Mut)(Fig. 5a). Moreover, we found that circ-PSMC3 significantly increased the PTEN mRNA levels, whereas co-transfection of circ-PSMC3 and miR-296-5p may cancel out this effect in MGC803 and AGS cells (Fig. 5b). Western blot showed that circ-PSMC3 could promote PTEN expression, while co-transfection of circ-PSMC3 and miR-296-5p had no effect on PTEN level (Fig. 5c). These results demonstrated that circPSMC3



could regulate PTEN expression by acting as a competing endogenous RNA to sponge miR-296-5p. Results of the malignant behavior of circPSMC3 and miR-296-5p on GC cell proliferation, viability, invasion migration and metastasis indicated that the circ-PSMC3 could inhibit proliferation, invasion and migration of GC cells. However, co-transfection of circPSMC3 and miR-296-5p may counteract this effect (Fig. 5d-h). These results of experiments suggested that CircPSMC3 suppresses the proliferation, invasion and migration of gastric cancer cells by sponging miR-296-5p to regulate PTEN.


Circ-PSMC3 inhibits the growth and metastasis of gastric cancer in vivo

To explore the association between circPSMC3 and the growth as well as metastasis of gastric cancer in vivo, MGC803 cells transfected with circPSMC3 and GFP was injected into nude mice to established xenograft tumor

model and metastasis nude mice model (Fig. 6a). In xenograft tumor model, we found that over expressing of circPSMC3 generated a negative effect on the volume of nude mice (Fig. 6b) as well as the weight (Fig. 6c). Ectopic over-expression of circPSMC3 inhibited metastasis in the lung compared to normal expression of circPSMC3 (Fig. 6d). Taken together, we illustrated that the over-expression of circPSMC3 could inhibit the proliferation, invasion and metastasis of GC cells and then suppress the progression of GC by sponging miR-296-5p to regulate PTEN expression (Fig. 6e).

Discussion

Deep sequencing combined with novel bioinformatics approaches led to the discovery that a significant portion of the human transcriptome is spliced into RNA loops [21]. In the last few years, several research groups have published interesting results, shedding light on the




biogenesis of circRNAs and possible mechanisms involving them [22]. Some of these discoveries have shown that circRNAs are very stable, abundant and present a tissue-specific expression pattern [23].

In our study, we confirmed that circPSMC3 was significantly lower expressed in GC plasmas, tissues and cells compared to normal controls. Clinicopathological features illustrated that down expression of circPSMC3 was negatively associated with TNM stage and lymphatic metastasis, with a reduced overall survival time for GC patients. More and more studies have explored the relationship between circRNAs and the development of gastric cancer from a clinical perspective and investigated its application as a tumor biomarker in clinic. For example, Xie Y et al. detected the expression levels of hsa_circ_0074362 in 127 gastric cancer tissues and

paired adjacent normal tissues by quantitative reverse transcription-polymerase chain reaction. Results showed hsa_circ_0074362 levels were significantly down regulated in gastric cancer tissues, gastritis tissues and gastric cancer cell lines and were associated with lymphatic metastasis, which may be a potential biomarker of gastric cancer [24]. However, most of the studies only detect the expression of circRNAs from cancer tissues and adjacent tissue. Only a small number of studies detect the expression of circRNAs from preoperative blood in GC patients and the sample size is small. The results of our study make circPSMC3 an ideal noninvasive biomarker for the diagnosis and prognosis of gastric cancer.


We demonstrated that miR-296-5p targets PTEN and promotes the proliferation and invasion of GC cells. Current studies show that miR-296-5p plays a role in



cancers. For example, Lee H et al. observed that miR-296-5p promoted the invasion of various glioblastomas cells. From results obtained from Ago2 immunoprecipitation and luciferase assays, they found that miR-296-5p downregulated CASP8 and NGFR through direct interaction between seed sequence of the miRNA and 3'UTR of the target mRNA. Collectively, their results implicated miR-296-5p as a potential cause of invasiveness in cancer and identifies miR-296-5p as a promising therapeutic target for glioblastomas [25]. Maia D reported miR-296-5p expression is associated with resistance to radiotherapy and tumor recurrence in early stage laryngeal squamous cell carcinoma, showing the feasibility of this marker as a novel prognostic factor for this malignancy. Furthermore, miR-296-5p expression


could be helpful in the identification of tumors resistant to radiotherapy, thus informing treatment plans [26]. Interestingly, Lee KH reported that miR-296-5p has a tumor-suppressive role by targeting Pin1. This suggested that there are likely prognostic and clinical applications of miR-296-5p in prostate cancer therapy [27]. In gastric cancer, Li T et al. showed miR-296-5p over-expression significantly promoted GC cell growth and attenuated the CDX1-induced anti-growth effects by recurring cell cycle distribution and apoptotic status, whereas knock-down of miR-296-5p decreased GC cell growth [28], which is consistent with our result.

There are accumulating examples of circRNAs acting as miRNA sponges, thereby influencing the posttranscriptional actions of miRNAs as suppressors of the



translation and/or stability of target mRNAs [29, 30]. For example, cir-ITCH (Itchy E3 ubiquitin protein ligase) was reported to sponge miR-7, miR-17, and miR-214, leading to the upregulation of ITCH and the inhibition of WNT signaling in esophageal squamous cell carcinoma [31]. Li X found that hsa_circ_103809 could bind to miR-620 and negatively regulates miR-620 expression, further inhibiting the proliferation and invasion abilities of hepatocellular carcinoma cells [32]. In our research, we discovered that the over-expression of circPSMC3 could inhibit the proliferation, invasion and metastasis of GC cells. Furthermore, it can suppress the progression of GC by regulating miR-296-5p and PTEN

expression. Functional inactivation of the tumor suppressor protein PTEN has been detected in multiple cases of GC, and already shown to be closely linked to the development, progression and prognosis of the disease. Inactivation of PTEN can be attributed to gene mutation, loss of heterozygosity, promoter hypermethylation, microRNA-mediated regulation of gene expression, and post-translational phosphorylation. PTEN is also involved in mechanisms regulating tumor resistance to chemotherapy [33]. Liu S et al. reported that low expression of PTEN and increased expression of miR-718 in GC tissues were both independent and unfavorable prognostic factors of GC. Up regulation of miR-718



could increase PI3K/Akt signaling by directly down regulating PTEN, thus promoting the proliferation and invasion of gastric cancer cells [34]. Liu T found that Circ-ZFR and PTEN were low-expressed whereas miR-107 and miR-130a were high-expressed in GC tissues and cells. There are targeted relationships and interactions between miR-130a/miR-107 and ZFR/PTEN. Circ-ZFR inhibits GC cell propagation, cell cycle and promoted apoptosis by sponging miR-107/miR-130a, while miR-107/miR-130a promoted GC cell propagation and prevented apoptosis through targeting PTEN. Circ-ZFR inhibited cell proliferation and facilitated apoptosis in GC by sponging miR-130a/miR-107 and modulating PTEN. Circ-ZFR curbed GC tumor growth and affected p53 protein expression in vivo [35]. To our knowledge, this is the first study to investigate the role of circPSMC3 in gastric cancer. Not only that, this is also the first article to study the relationship between miR-296-5p and PTEN. These findings may bring light to the treatment of GC.

There are several limitations to the interpretation of our study results. Firstly, our study uses GC samples taken from an ethnically homogenous population and expects further sample size and more validation from different regions. Secondly, our study examines the

ability of circPSMC3 to bind to miR-296-5p, but there may be other miRNAs that binds circPSMC3 to regulate the occurrence and progression of GC. Thirdly, whether circPSMC3 regulates the development of GC through other mechanisms such as protein binding requires further investigation. We hope that a follow-up study will elucidate a deeper understanding of the therapeutic potential of circPSMC3.

Conclusion

Our study identifies a new circular RNA, termed circPSMC3 that is down-regulated in tissues, corresponding plasmas from GC patients as well as GC cell lines and can act as a sponge of miRNA-296-5p to regulate the expression of PTEN. Our findings reveal a novel potential circulating biomarker for detection of GC.

Additional file

Additional file 1: Figure S1. (a) A total of 6 circRNAs based on the multiple fold difference in circRNA microarray and then were verified in a small sample of plasmas by using qRT-PCR. (b) siRNA against circPSMC3 were designed to silence circPSMC3 level in BGC823 cells. (c) siRNA against circPSMC3 were designed to silence circPSMC3 level in SGC7901 cells. (d) siRNA#1 against circPSMC3 were designed to silence circPSMC3 without influencing PSMC3 mRNA level in BGC823 and SGC7901 cells. (e)

The expression of circPSMC3 was evaluated in MGC803 and AGS cells transfected with circPSMC3 vector or Mock by using qRT-PCR. (f) The expression of PSMC3 mRNA was evaluated in MGC803 and AGS cells transfected with circPSMC3 vector or Mock by using qRT-PCR. (g) The expression of miR-296-5p was evaluated in MGC803 and AGS cells transfected with miR-296-5p inhibitor or miR-NC. (h) The expression of miR-296-5p was evaluated in MGC803 and AGS cells transfected with miR-296-5p mimics or miR-NC. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. (DOCX 722 kb)

Abbreviations

CCK8: Cell counting kit-8; ceRNA: competitive endogenous RNA; circRNAs: Circular RNAs; EdU: 5-Ethynyl-20- deoxyuridine; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; GC: Gastric cancer; GO: Gene ontology; IgG: immunoglobulin G; KEGG: Kyoto Encyclopedia of Genes and Genomes; miRNAs: MicroRNAs; PTEN: Phosphatase and Tensin Homology; qRT-PCR: Quantitative reverse transcription polymerase reaction; RIP: RNA immunoprecipitation; RNA-FISH: RNA fluorescence in situ hybridization; ROC: Receiver-operating characteristic; WT: Wild type

Acknowledgements

We are grateful for participation and cooperation from the patients with gastric cancer.

Funding

This project was supported by Natural Science of Jiangsu Province (BK20151087) and the Development of Medical Science and Technology Foundation of Nanjing (Grant No.YKK17117) to Professor Hongyong Cao, the National Natural Science Foundation of China (Grant No.81572557 and 81872114) to Professor Shuli Zhao, and Natural Science Foundation of Nanjing medical university (Grant No.NMUB2018328) to Doctor Weiwei Tang.

Availability of data and materials

The datasets obtained and analyzed during the current study were available from the corresponding authors in a reasonable request.

Authors' contributions

There are 2 first authors in this manuscript and they have equally contributed to this project. DWR was responsible for collecting GC tissue specimen and their adjacent nontumorous tissues, as well as drafting the manuscript. CL was responsible for designing and performing the experiments. BZ was responsible for the manuscript language editing and data analysis. KF also contributed to performing part of the experiments, and data interpretation. Furthermore, we have three corresponding authors in this manuscript. SLZ has contributed to data interpretation, editing and critical revision of the manuscript. WWT and HYC have contributed to study design and critical revision of the manuscript. SLZ, WWT, and HYC were also responsible for handling the revisions and re-submission of revised manuscripts. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The human cancer tissues used in this study were approved by the Ethics Committee of Nanjing First Hospital, Nanjing Medical University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. ²Michael G. DeGroot School of Medicine, McMaster University, Hamilton, Ontario, Canada. ³Department of General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.

Received: 29 September 2018 Accepted: 13 February 2019

Published online: 18 February 2019

References

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in Globocan. *Int J Cancer*. 2015;136:E359–86.
2. Valastyan S, Weinberg RA. Tumor Metastasis: Molecular insights and evolving paradigms. *Cell*. 2011;147:275–92.
3. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. *N Engl J Med*. 2001;345:784–9.
4. Zhuang M, Gao W, Xu J, et al. The long non-coding RNA H19-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1. *Biochem Biophys Res Commun*. 2014;448:315–22.
5. Ito K, Chuang LS, Ito T, et al. Loss of Runx3 is a key event in inducing precancerous state of the stomach. *Gastroenterology*. 2011;140:1536–1546e8.
6. Wilusz JE, Sharp PA. A circuitous route to noncoding RNA. *Science*. 2013;340:440e441.
7. Szabo L, Morey R, Palpant NJ, et al. Statistically based splicing detection reveals neural enrichment and tissue-specific induction of circular RNA during human fetal development. *Genome Biol*. 2015;16:126.
8. Salzman J, Chen RE, Olsen MN, et al. Brown, cell-type specific features of circular RNA expression. *PLoS Genet*. 2013;9:e1003777.
9. Li J, Yang J, Zhou P, Le Y, et al. Circular RNAs in cancer: novel insights into origins, properties, functions and implications. *Am J Cancer Res*. 2015;5:472–80.
10. Hsiao K-Y, Lin Y-C, Gupta SK, et al. Non-coding effects of circular RNA CCDC66 promotes colon cancer growth and metastasis. *Cancer Res*. 2017;77:2339–50.
11. Du WW, Yang W, Liu E, et al. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. *Nucleic Acids Res*. 2016;44:2846e2858.
12. Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. *Nature*. 2013;495:384e388.
13. Holdt LM, Stahinger A, Sass K, et al. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. *Nat Commun*. 2016;7:12429.
14. Han D, Li J, Wang H, et al. Circular RNA circMTO1 acts as the sponge of MicroRNA-9 to suppress hepatocellular carcinoma progression. *Hepatology*. 2017;66:1151–64.
15. Zhong Z, Huang M, Lv M, et al. Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway. *Cancer Letters*. 2017;403:305–17.
16. Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. *Nat Rev Genet*. 2016;17:272–83.
17. Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature*. 2013;495:333–8.
18. Chen L, Zhang S, Wu J, et al. circRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 family. *Oncogene*. 2017;36:4551–61.
19. Wei X, Li H, Yang J, et al. Circular RNA profiling reveals an abundant circLMO7 that regulates myoblasts differentiation and survival by sponging miR-378a-3p. *Cell Death Dis*. 2017;8(8):e3153.
20. Li Y, Zheng F, Xiao X, et al. CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells. *EMBO Rep*. 2017;18:1646–59.
21. Sheng JQ, Liu L, Wang MR, et al. Circular RNAs in digestive system cancer: potential biomarkers and therapeutic targets. *Am J Cancer Res*. 2018;8:1142–56.
22. Fang Y. Circular RNAs as novel biomarkers with regulatory potency in human diseases. *Future Sci OA*. 2018;4:FSO314.
23. Kristensen L, Hansen S, et al. Circular RNAs in cancer: opportunities and challenges in the field. *Oncogene*. 2017;37:555–65.
24. Xie Y, Shao Y, Sun W, et al. Downregulated expression of hsa_circ_0074362 in gastric cancer and its potential diagnostic values. *Biomark Med*. 2018;12:11–20.
25. Lee H, Shin CH, Kim HR, et al. MicroRNA-296-5p promotes invasiveness through downregulation of nerve growth factor receptor and Caspase-8. *Mol Cells*. 2017;40:254–61.
26. Maia D, de Carvalho AC, Horst MA, et al. Expression of miR-296-5p as predictive marker for radiotherapy resistance in early-stage laryngeal carcinoma. *J Transl Med*. 2015;13:262.

27. Lee KH, Lin FC, Hsu TI, et al. MicroRNA-296-5p (miR-296-5p) functions as a tumor suppressor in prostate cancer by directly targeting Pin1. *Biochim Biophys Acta*. 1843;2014:2055–66.
28. Li T, Lu YY, Zhao XD, et al. MicroRNA-296-5p increases proliferation in gastric cancer through repression of caudal-related homeobox 1. *Oncogene*. 2014;33:783–93.
29. Qu D, Yan B, Xin R, Ma T, et al. A novel circular RNA hsa_circ_0020123 exerts oncogenic properties through suppression of miR-144 in non-small cell lung cancer. *Am J Cancer Res*. 2018;8:1387–402.
30. Xiao T, Xue J, Shi M, et al. Circ008913, via miR-889 regulation of DAB2IP/ZEB1, is involved in the arsenite-induced acquisition of CSC-like properties by human keratinocytes in carcinogenesis. *Metallomics*. 2018;10:1328–38.
31. Yang C, Yuan W, Yang X, et al. Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression. *Mol Cancer*. 2018;17:19.
32. Li X, Shen M. Circular RNA hsa_circ_103809 suppresses hepatocellular carcinoma proliferation and invasion by sponging miR-620. *Eur Rev Med Pharmacol Sci*. 2019;23:555–66.
33. Xu WT, Yang Z, Lu NH, et al. Roles of PTEN (phosphatase and Tensin homolog) in gastric cancer development and progression. *Asian Pac J Cancer Prev*. 2014;15:17–24.
34. Liu S, Tian Y, Zhu C, et al. High miR-718 suppresses phosphatase and Tensin homolog (PTEN) expression and correlates to unfavorable prognosis in gastric Cancer. *Med Sci Monit*. 2018;24:5840–50.
35. Liu T, Liu S, Xu Y, et al. Circular RNA-ZFR inhibited cell proliferation and promoted apoptosis in gastric Cancer by sponging miR-130a/miR-107 and modulating PTEN. *Cancer Res Treat*. 2018;50(4):1396–417.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

